NASDAQ:FTSV

Forty Seven Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

$95.51

0.00 (0.00 %)

(As of 04/7/2020)

Add

Compare

Today's Range

$95.51

Now: $95.51▼

$95.51

50-Day Range

$95.51

MA: $95.51▼

$95.51

52-Week Range

$5.53

Now: $95.51▼

$95.51

VolumeN/A

Average Volume1.61 million shs

Market Capitalization$4.60 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.4

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:FTSV

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.fortyseveninc.com

Phone650-352-4150

Employees57

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio14.81

Quick Ratio14.81

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$15.68 million

Price / Sales293.33

Cash FlowN/A

Price / Cash FlowN/A

Book Value$7.52 per share

Price / Book12.70

Profitability

EPS (Most Recent Fiscal Year)($2.34)

Net Income$-87,620,000.00

Net MarginsN/A

Return on Equity-50.38%

Return on Assets-44.35%

Miscellaneous

Outstanding Shares48,156,000

Market Cap$4.60 billion

Next Earnings DateN/A

OptionableNot Optionable

Headlines

The Lunacy Of Chasing Stocks At 100 Times Sales: A 5-Stock Warning List
February 16, 2021 | forbes.com

FORTY SEVEN INC. (4C8.DU)
October 12, 2020 | in.finance.yahoo.com

Forty Seven Inc. Registered Sha (4C8.SG)
October 10, 2020 | au.finance.yahoo.com

Gilead Sciences: Debt Fueled Bottom
September 25, 2020 | seekingalpha.com

FORTY SEVEN INC. (4C8.BE)
August 20, 2020 | ca.finance.yahoo.com

Did Hedge Funds Make The Right Call On Euronet Worldwide, Inc. (EEFT)
July 13, 2020 | finance.yahoo.com

Were Hedge Funds Right About HD Supply Holdings Inc (HDS)?
July 8, 2020 | finance.yahoo.com

Hedge Funds Intensely Selling Euronet Worldwide, Inc. (EEFT)
June 12, 2020 | finance.yahoo.com

Hedge Funds Warming Up To HD Supply Holdings Inc (HDS)
June 1, 2020 | finance.yahoo.com

Why Forty Seven Stock Skyrocketed 64.5% in March
April 8, 2020 | www.fool.com

Gilead completes Forty Seven buy
April 7, 2020 | seekingalpha.com

Gilead nearing finish line on Forty Seven buy
March 30, 2020 | seekingalpha.com

FTSV, MEET, MINI, and NTGN SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
March 24, 2020 | finance.yahoo.com

6 Stocks To Watch For March 23, 2020
March 23, 2020 | www.benzinga.com

Forty Seven EPS beats by $0.10
March 20, 2020 | seekingalpha.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds DLPH, FTSV, SMRT, and FHN Shareholders About Its Ongoing Investigations
March 20, 2020 | finance.yahoo.com

Iovance Biotheraputics: Still Well-Poised To Treat Solid Tumors
March 20, 2020 | seekingalpha.com

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - ETFC, FTSV, MEET
March 19, 2020 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - FTSV, MINI, FSB
March 17, 2020 | finance.yahoo.com

MERGER ALERT - FTSV, GCAP, and WSC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
March 11, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.02 out of 5 stars

Medical Sector

1039th out of 2,021 stocks

Pharmaceutical Preparations Industry

475th out of 772 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Forty Seven.

2.6 Community Rank

Outperform Votes
Forty Seven has received 141 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Forty Seven has received 132 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Forty Seven has received 51.65% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote “Outperform” if you believe FTSV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Forty Seven does not currently pay a dividend.
Dividend Growth
Forty Seven does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Forty Seven insiders have not sold or bought any company stock.
Percentage Held by Insiders
37.40% of the stock of Forty Seven is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
71.77% of the stock of Forty Seven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Forty Seven are expected to decrease in the coming year, from ($3.04) to ($3.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Forty Seven is -38.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Forty Seven is -38.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Forty Seven has a P/B Ratio of 12.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Receive FTSV News and Ratings via Email

Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter.

Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

What stocks does MarketBeat like better than Forty Seven?

Wall Street analysts have given Forty Seven a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Forty Seven wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) released its earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.38). The firm had revenue of $15.68 million for the quarter, compared to the consensus estimate of $15.80 million.
View Forty Seven's earnings history.

Who are Forty Seven's key executives?

Forty Seven's management team includes the following people:

Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)
Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)
Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)
Mr. Mark Chao, Founder & VP of Clinical Devel.
Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.

Who are some of Forty Seven's key competitors?

Some companies that are related to Forty Seven include Alnylam Pharmaceuticals (ALNY), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Dr. Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), Maravai LifeSciences (MRVI), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO) and Ultragenyx Pharmaceutical (RARE).
View all of FTSV's competitors.

What other stocks do shareholders of Forty Seven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forty Seven investors own include Sorrento Therapeutics (SRNE), Energy Transfer (ET), TG Therapeutics (TGTX), Gilead Sciences (gild), Unisys (UIS), Inovio Pharmaceuticals (INO), GlycoMimetics (GLYC), NVIDIA (NVDA), ACADIA Pharmaceuticals (ACAD) and Sarepta Therapeutics (SRPT).

When did Forty Seven IPO?

(FTSV) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

What is Forty Seven's stock symbol?

Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."

What is Forty Seven's stock price today?

One share of FTSV stock can currently be purchased for approximately $95.51.

How much money does Forty Seven make?

Forty Seven has a market capitalization of $4.60 billion and generates $15.68 million in revenue each year. The company earns $-87,620,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

How many employees does Forty Seven have?

Forty Seven employs 57 workers across the globe.

What is Forty Seven's official website?

The official website for Forty Seven is www.fortyseveninc.com.

Where are Forty Seven's headquarters?

Forty Seven is headquartered at 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025.

How can I contact Forty Seven?

Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]

This page was last updated on 4/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Forty Seven Stock Forecast, Price & News

Adding

Adding

Adding Forty Seven Inc

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Headlines

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

2.6 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

2.5 Company Ownership

0.0 Earnings and Valuation

Receive FTSV News and Ratings via Email

Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

What stocks does MarketBeat like better than Forty Seven?

How were Forty Seven's earnings last quarter?

Who are Forty Seven's key executives?

Who are some of Forty Seven's key competitors?

What other stocks do shareholders of Forty Seven own?

When did Forty Seven IPO?

What is Forty Seven's stock symbol?

What is Forty Seven's stock price today?

How much money does Forty Seven make?

How many employees does Forty Seven have?

What is Forty Seven's official website?

Where are Forty Seven's headquarters?

How can I contact Forty Seven?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™